Halozyme’s Spotlight Shifts To Enhanze Exclusively After PEGPH20 Fails In Phase III
The Enhanze drug delivery technology, which is expected to be profitable starting next year, takes center stage as Halozyme discontinues PEGPH20 development and cuts its oncology operations along with 160 jobs.
You may also be interested in...
The California biotech's Phase II pancreatic cancer candidate demcizumab failed to show benefit versus placebo for progression-free or overall survival. Meanwhile, Bayer decided not to exercise its options on a pair of Wnt pathway candidates under a 2010 collaboration with OncoMed.
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
As Takeda pays down debt associated with the acquisition of Shire and advances R&D programs toward global filings, the company is selling its growth plan to investors – but are they buying?